Vivani Medical (NASDAQ:VANI) Stock Rating Upgraded by Wall Street Zen

Vivani Medical (NASDAQ:VANI) was upgraded by research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued on Saturday.

Other equities analysts have also recently issued reports about the company. Weiss Ratings raised Vivani Medical from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, July 7th. Lake Street Capital initiated coverage on Vivani Medical in a research report on Tuesday, June 23rd. They set a “buy” rating and a $4.00 price objective for the company. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $3.75.

Vivani Medical Price Performance

Shares of VANI opened at $1.40 on Friday. Vivani Medical has a 1-year low of $0.92 and a 1-year high of $1.92. The stock has a market cap of $120.74 million, a price-to-earnings ratio of -4.00 and a beta of 2.35. The firm has a 50 day simple moving average of $1.29 and a 200-day simple moving average of $1.24.

Vivani Medical (NASDAQ:VANI) last posted its earnings results on Thursday, August 13th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.01. On average, equities analysts expect that Vivani Medical will post -0.3 earnings per share for the current fiscal year.

Insider Transactions at Vivani Medical

In other Vivani Medical news, Director Gregg Williams purchased 1,587,301 shares of the firm’s stock in a transaction on Monday, June 15th. The shares were purchased at an average cost of $1.26 per share, with a total value of $1,999,999.26. Following the purchase, the director owned 36,119,086 shares in the company, valued at approximately $45,510,048.36. This represents a 4.60% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Insiders own 53.30% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Citadel Advisors LLC purchased a new position in shares of Vivani Medical during the 3rd quarter worth about $26,000. Susquehanna International Group LLP grew its holdings in Vivani Medical by 100.5% in the third quarter. Susquehanna International Group LLP now owns 32,314 shares of the company’s stock valued at $46,000 after purchasing an additional 16,200 shares during the period. Jane Street Group LLC purchased a new stake in Vivani Medical in the fourth quarter valued at approximately $60,000. Renaissance Technologies LLC grew its holdings in Vivani Medical by 118.4% in the fourth quarter. Renaissance Technologies LLC now owns 97,985 shares of the company’s stock valued at $121,000 after purchasing an additional 53,127 shares during the period. Finally, Marshall Wace LLP acquired a new position in Vivani Medical during the fourth quarter worth approximately $174,000. Institutional investors and hedge funds own 6.78% of the company’s stock.

Vivani Medical Company Profile

Vivani Medical Solutions, Inc (NASDAQ: VANI) is a medical technology company focused on the design, development and commercialization of advanced specimen retrieval and hemostasis products for minimally invasive diagnostic procedures. Its core mission is to enhance procedural safety and streamline clinical workflows for interventional radiologists and pathology laboratories.

The company’s flagship offerings include the StopBleed Retrieval Device and StopBleed Pad, which integrate proprietary hemostatic materials to control bleeding at biopsy sites and preserve tissue integrity.